2026 Q3 - tulosraportti
Äänite tulossa
Tänään
3,0812 USD/osake
Viimeisin osinko
2,04%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 27.10. | ||
2026 Q2 - tulosraportti 21.7. | ||
2026 Q1 - tulosraportti 28.4. | ||
Vuosittainen yhtiökokous 2026 6.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·30.5.2024Some good information to take with you here: ### Goldman Sachs The latest developments surrounding Goldman Sachs include them being involved in a significant restructuring of their business model and management. The company has been active in adjusting its portfolio and focusing on core businesses to increase profitability. In addition, Goldman Sachs has also been under regulatory scrutiny for some of its past transactions and investment strategies. This has led to an increased effort to ensure compliance with regulatory requirements and improve internal management. ### Novartis Novartis has recently announced a number of significant news and advances: 1. **Acquisition of MorphoSys AG**: Novartis has secured the approval of 79.6% of the shareholders of MorphoSys for an acquisition valued at 2.7 billion euros. The acquisition strengthens Novartis' oncology portfolio, particularly with access to pelabresib, a potential new treatment for myelofibrosis, and tulmimetostat, which is in early phase clinical trials for solid tumors and lymphomas. The agreement is expected to be completed during the first half of 2024 [oai_citation:1,Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash | Novartis](https://www.novartis.com/news/media-releases/novartis-meets-all-tender-offer-conditions-acquire-morphosys-ag-eur-68-share-cash) [oai_citation:2, Novartis to swallow German cancer-drug maker](https://medicalxpress.com/news/2024-02-novartis-swallow-german-cancer-drug.html). 2. **Financial Results Q1 2024**: Novartis reported double-digit growth in sales and operating margin in the first quarter of 2024. Net sales increased 11% compared to the same period last year, driven by strong sales of key products such as Entresto, Cosentyx and Kesimpta. The company has also raised its guidance for the whole year, with expectations of continued growth in both sales and operating income [oai_citation:3,Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised | Novartis](https://www.novartis.com/news/media-releases/novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-q1-fy-2024-guidance-raised) [ oai_citation:4,Novartis Financial Results – Q1 2024 | Novartis](https://www.novartis.com/news/novartis-financial-results-q1-2024). These developments show that both Goldman Sachs and Novartis are in a phase of significant strategic adjustment and growth, which affects their market position and future prospects.
5.10.2023Does anyone know what will happen at Nordnet with the Sandoz spin-offed shares?Whoever applies gets an answer, you can see if you become any wiser from this. Data collected from various places. Regarding the Sandoz spinoff and what happens to the shares in Nordnet, there are some important points to note: 1. **Distribution of Shares**: The spinoff was carried out by Novartis shareholders receiving one Sandoz share for every five Novartis shares they owned. This distribution was made as a dividend in the form of shares [oai_citation:1,Sandoz spin-off | Novartis](https://www.novartis.com/news/sandoz-spinoff) [oai_citation:2,Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company | Novartis](https://www.novartis.com/news/media-releases/novartis-executes-sandoz-spin-completing-strategic-transformation-leading-focused-innovative-medicines-company). 2. **Nordnet accounts**: For shareholders who hold Novartis shares on Nordnet, the Sandoz shares will automatically be added to their account. This means that you do not need to do anything to receive the new shares. 3. **Trading and Listing**: The Sandoz shares are listed on the SIX Swiss Exchange under the ticker code "SDZ". The shares can be traded on the stock exchange from the day the spinoff was completed, and this also applies to those distributed to Novartis shareholders via Nordnet [oai_citation:3,Sandoz spin-off | Novartis](https://www.novartis.com/news/sandoz-spinoff) [oai_citation:4,Sandoz spin-off successfully completed](https://www.computershare.com/ch/en/news/sandoz- spin-off-successfully-completed). This means that if you had Novartis shares on Nordnet before the spinoff, you will now find Sandoz shares added to your portfolio. It is always a good idea to check your Nordnet account to confirm that the shares have been added correctly.
1.2.2023 · Muokattu𝐉𝐄𝐅𝐅𝐄𝐑𝐈𝐄𝐒 𝐝𝐨𝐰𝐧𝐠𝐫𝐚𝐝𝐞𝐬 𝐍𝐎𝐕𝐀𝐑𝐓𝐈𝐒 𝐀𝐆 𝐭𝐨 '𝐛𝐮𝐲' The analysis house Jefferies has left the rating for Novartis for the fourth quarter of 2022 on "Buy" with a target price of CHF 100. While sales were two percent below the consensus estimate, earnings beat it by six percent. The pharmaceutical company's drug Pluvicto has developed particularly well, while Cosentyx has disappointed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
Äänite tulossa
Tänään
3,0812 USD/osake
Viimeisin osinko
2,04%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·30.5.2024Some good information to take with you here: ### Goldman Sachs The latest developments surrounding Goldman Sachs include them being involved in a significant restructuring of their business model and management. The company has been active in adjusting its portfolio and focusing on core businesses to increase profitability. In addition, Goldman Sachs has also been under regulatory scrutiny for some of its past transactions and investment strategies. This has led to an increased effort to ensure compliance with regulatory requirements and improve internal management. ### Novartis Novartis has recently announced a number of significant news and advances: 1. **Acquisition of MorphoSys AG**: Novartis has secured the approval of 79.6% of the shareholders of MorphoSys for an acquisition valued at 2.7 billion euros. The acquisition strengthens Novartis' oncology portfolio, particularly with access to pelabresib, a potential new treatment for myelofibrosis, and tulmimetostat, which is in early phase clinical trials for solid tumors and lymphomas. The agreement is expected to be completed during the first half of 2024 [oai_citation:1,Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash | Novartis](https://www.novartis.com/news/media-releases/novartis-meets-all-tender-offer-conditions-acquire-morphosys-ag-eur-68-share-cash) [oai_citation:2, Novartis to swallow German cancer-drug maker](https://medicalxpress.com/news/2024-02-novartis-swallow-german-cancer-drug.html). 2. **Financial Results Q1 2024**: Novartis reported double-digit growth in sales and operating margin in the first quarter of 2024. Net sales increased 11% compared to the same period last year, driven by strong sales of key products such as Entresto, Cosentyx and Kesimpta. The company has also raised its guidance for the whole year, with expectations of continued growth in both sales and operating income [oai_citation:3,Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised | Novartis](https://www.novartis.com/news/media-releases/novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-q1-fy-2024-guidance-raised) [ oai_citation:4,Novartis Financial Results – Q1 2024 | Novartis](https://www.novartis.com/news/novartis-financial-results-q1-2024). These developments show that both Goldman Sachs and Novartis are in a phase of significant strategic adjustment and growth, which affects their market position and future prospects.
- 5.10.2023Does anyone know what will happen at Nordnet with the Sandoz spin-offed shares?Whoever applies gets an answer, you can see if you become any wiser from this. Data collected from various places. Regarding the Sandoz spinoff and what happens to the shares in Nordnet, there are some important points to note: 1. **Distribution of Shares**: The spinoff was carried out by Novartis shareholders receiving one Sandoz share for every five Novartis shares they owned. This distribution was made as a dividend in the form of shares [oai_citation:1,Sandoz spin-off | Novartis](https://www.novartis.com/news/sandoz-spinoff) [oai_citation:2,Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company | Novartis](https://www.novartis.com/news/media-releases/novartis-executes-sandoz-spin-completing-strategic-transformation-leading-focused-innovative-medicines-company). 2. **Nordnet accounts**: For shareholders who hold Novartis shares on Nordnet, the Sandoz shares will automatically be added to their account. This means that you do not need to do anything to receive the new shares. 3. **Trading and Listing**: The Sandoz shares are listed on the SIX Swiss Exchange under the ticker code "SDZ". The shares can be traded on the stock exchange from the day the spinoff was completed, and this also applies to those distributed to Novartis shareholders via Nordnet [oai_citation:3,Sandoz spin-off | Novartis](https://www.novartis.com/news/sandoz-spinoff) [oai_citation:4,Sandoz spin-off successfully completed](https://www.computershare.com/ch/en/news/sandoz- spin-off-successfully-completed). This means that if you had Novartis shares on Nordnet before the spinoff, you will now find Sandoz shares added to your portfolio. It is always a good idea to check your Nordnet account to confirm that the shares have been added correctly.
- 1.2.2023 · Muokattu𝐉𝐄𝐅𝐅𝐄𝐑𝐈𝐄𝐒 𝐝𝐨𝐰𝐧𝐠𝐫𝐚𝐝𝐞𝐬 𝐍𝐎𝐕𝐀𝐑𝐓𝐈𝐒 𝐀𝐆 𝐭𝐨 '𝐛𝐮𝐲' The analysis house Jefferies has left the rating for Novartis for the fourth quarter of 2022 on "Buy" with a target price of CHF 100. While sales were two percent below the consensus estimate, earnings beat it by six percent. The pharmaceutical company's drug Pluvicto has developed particularly well, while Cosentyx has disappointed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 27.10. | ||
2026 Q2 - tulosraportti 21.7. | ||
2026 Q1 - tulosraportti 28.4. | ||
Vuosittainen yhtiökokous 2026 6.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
Äänite tulossa
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 27.10. | ||
2026 Q2 - tulosraportti 21.7. | ||
2026 Q1 - tulosraportti 28.4. | ||
Vuosittainen yhtiökokous 2026 6.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,0812 USD/osake
Viimeisin osinko
2,04%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·30.5.2024Some good information to take with you here: ### Goldman Sachs The latest developments surrounding Goldman Sachs include them being involved in a significant restructuring of their business model and management. The company has been active in adjusting its portfolio and focusing on core businesses to increase profitability. In addition, Goldman Sachs has also been under regulatory scrutiny for some of its past transactions and investment strategies. This has led to an increased effort to ensure compliance with regulatory requirements and improve internal management. ### Novartis Novartis has recently announced a number of significant news and advances: 1. **Acquisition of MorphoSys AG**: Novartis has secured the approval of 79.6% of the shareholders of MorphoSys for an acquisition valued at 2.7 billion euros. The acquisition strengthens Novartis' oncology portfolio, particularly with access to pelabresib, a potential new treatment for myelofibrosis, and tulmimetostat, which is in early phase clinical trials for solid tumors and lymphomas. The agreement is expected to be completed during the first half of 2024 [oai_citation:1,Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash | Novartis](https://www.novartis.com/news/media-releases/novartis-meets-all-tender-offer-conditions-acquire-morphosys-ag-eur-68-share-cash) [oai_citation:2, Novartis to swallow German cancer-drug maker](https://medicalxpress.com/news/2024-02-novartis-swallow-german-cancer-drug.html). 2. **Financial Results Q1 2024**: Novartis reported double-digit growth in sales and operating margin in the first quarter of 2024. Net sales increased 11% compared to the same period last year, driven by strong sales of key products such as Entresto, Cosentyx and Kesimpta. The company has also raised its guidance for the whole year, with expectations of continued growth in both sales and operating income [oai_citation:3,Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised | Novartis](https://www.novartis.com/news/media-releases/novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-q1-fy-2024-guidance-raised) [ oai_citation:4,Novartis Financial Results – Q1 2024 | Novartis](https://www.novartis.com/news/novartis-financial-results-q1-2024). These developments show that both Goldman Sachs and Novartis are in a phase of significant strategic adjustment and growth, which affects their market position and future prospects.
- 5.10.2023Does anyone know what will happen at Nordnet with the Sandoz spin-offed shares?Whoever applies gets an answer, you can see if you become any wiser from this. Data collected from various places. Regarding the Sandoz spinoff and what happens to the shares in Nordnet, there are some important points to note: 1. **Distribution of Shares**: The spinoff was carried out by Novartis shareholders receiving one Sandoz share for every five Novartis shares they owned. This distribution was made as a dividend in the form of shares [oai_citation:1,Sandoz spin-off | Novartis](https://www.novartis.com/news/sandoz-spinoff) [oai_citation:2,Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company | Novartis](https://www.novartis.com/news/media-releases/novartis-executes-sandoz-spin-completing-strategic-transformation-leading-focused-innovative-medicines-company). 2. **Nordnet accounts**: For shareholders who hold Novartis shares on Nordnet, the Sandoz shares will automatically be added to their account. This means that you do not need to do anything to receive the new shares. 3. **Trading and Listing**: The Sandoz shares are listed on the SIX Swiss Exchange under the ticker code "SDZ". The shares can be traded on the stock exchange from the day the spinoff was completed, and this also applies to those distributed to Novartis shareholders via Nordnet [oai_citation:3,Sandoz spin-off | Novartis](https://www.novartis.com/news/sandoz-spinoff) [oai_citation:4,Sandoz spin-off successfully completed](https://www.computershare.com/ch/en/news/sandoz- spin-off-successfully-completed). This means that if you had Novartis shares on Nordnet before the spinoff, you will now find Sandoz shares added to your portfolio. It is always a good idea to check your Nordnet account to confirm that the shares have been added correctly.
- 1.2.2023 · Muokattu𝐉𝐄𝐅𝐅𝐄𝐑𝐈𝐄𝐒 𝐝𝐨𝐰𝐧𝐠𝐫𝐚𝐝𝐞𝐬 𝐍𝐎𝐕𝐀𝐑𝐓𝐈𝐒 𝐀𝐆 𝐭𝐨 '𝐛𝐮𝐲' The analysis house Jefferies has left the rating for Novartis for the fourth quarter of 2022 on "Buy" with a target price of CHF 100. While sales were two percent below the consensus estimate, earnings beat it by six percent. The pharmaceutical company's drug Pluvicto has developed particularly well, while Cosentyx has disappointed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt